Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Kevin J. Curran"'
Autor:
Brigitte Senechal, Mark B. Geyer, Marco L. Davila, Kevin J. Curran, Mithat Gonen, Mikhail Roshal, Isabelle Riviere, Michel Sadelain, Peter Maslak, Jessica Flynn, Kitsada Wudhikarn, Claudia Diamonte, Renier J. Brentjens, Jae H. Park, Xiuyan Wang, Elizabeth Halton
Publikováno v:
Blood
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult
Autor:
Christopher J. Forlenza, Brigitte Senechal, Nancy A. Kernan, Susan E. Prockop, Yasmin Khakoo, David A. Williams, Isabelle Riviere, Peter G. Steinherz, Craig S. Sauter, Jaap Jan Boelens, Michel Sadelain, Lewis B. Silverman, Farid Boulad, Glenn Heller, Richard J. O'Reilly, Victoria Szenes, Jae H. Park, Barbara Spitzer, Neerav Shukla, Andrew L. Kung, Rachel Kobos, Steven P. Margossian, Renier J. Brentjens, Xiuyan Wang, Maria Cancio, Kevin J Curran
Publikováno v:
Blood. 134:2361-2368
Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter clinical trial to determine toxicity, feasibility, and respo
Autor:
Steven P. Margossian, Rachel Wilcox, Michelle L. Hermiston, Holly L Pacenta, Heather E. Stefanski, Christina Baggott, Muna Qayed, Vanessa A Fabrizio, G.D. Myers, Snehit Prabhu, Vasant Chinnabhandar, Kevin J Curran, Michael R. Verneris, A. Yasemin Goksenin, Theodore W. Laetsch, Prakash Satwani, Christine L Phillips, Julie-An Talano, Crystal L. Mackall, Michael Kunicki, Liora M. Schultz, Amy Moskop, Nicole Karras, Patrick A. Brown, Cara A Rabik, Amy K. Keating, Jenna Rossoff, Christa Krupski
Publikováno v:
Blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d233911e1462c7c5bebdda65fda5c0
https://europepmc.org/articles/PMC8617436/
https://europepmc.org/articles/PMC8617436/
Autor:
Theodore W. Laetsch, Kevin J Curran, Michelle L. Hermiston, Prakash Satwani, Christina Baggott, Michael Kunicki, Crystal L. Mackall, Amy K. Keating, G.D. Myers, Vanessa A Fabrizio, Michael R. Verneris, Nicole Karras, Jenna Rossoff, Heather E. Stefanski, Christa Krupski, Christine L Phillips, Amy Moskop, Julie-An Talano, Rachel Wilcox, Steven P. Margossian, Holly L Pacenta, Snehit Prabhu, Cara A Rabik, Patrick A. Brown, Liora M. Schultz, A. Yasemin Goksenin, Muna Qayed, Vasant Chinnabhandar
Publikováno v:
Blood. 136:42-44
Introduction Chimeric antigen receptor (CAR) T cell therapy has been extremely efficacious in pediatric patients with multiply relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL) with overall remission rates of 81% by three months
Autor:
Andromachi Scaradavou, Maria Cancio, Celina L. Szanto, Mirjam E. Belderbos, Elizabeth Klein, Wouter J.W. Kollen, Farid Boulad, Nancy A. Kernan, Dorine Bresters, Marc Bierings, Stefan Nierkens, Kevin J. Curran, Barbara Spitzer, Coco de Koning, Jurgen Langenhorst, Jaap Jan Boelens, Birgitta Versluijs, Caroline A. Lindemans, Susan E. Prockop, Alwin D. R. Huitema, Ichelle van Roessel, Richard J. O'Reilly
Publikováno v:
Blood
Acute graft-versus-host-Disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). We previously showed that early CD4+ T-cell immune reconstitution (IR; CD4+ IR) predicts survival after HCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5555c041f4a96722046831f6ef4a6558
https://europepmc.org/articles/PMC7986048/
https://europepmc.org/articles/PMC7986048/
Autor:
Michelle L. Hermiston, Christina Baggott, A. Yasemin Goksenin, Michael Kunicki, Julie-An Talano, Theodore W. Laetsch, Steven P. Margossian, Michael R. Verneris, Christine L Phillips, Crystal L. Mackall, Vasant Chinnabhandar, Prakash Satwani, Kevin J. Curran, Nicole Karras, Liora M. Schultz, Heather E. Stefanski, Snehit Prabhu, Muna Qayed, Patrick A. Brown, Amy K. Keating, Amy Moskop, Jenna Rossoff, Christa Krupski, Cara A Rabik, Vanessa A Fabrizio, Holly L Pacenta, Rachel Wilcox, G.D. Myers
Publikováno v:
Blood. 136:14-15
Introduction: Chimeric Antigen Receptor (CAR) T cell therapy targeting CD19 has shifted our treatment approach for relapsed and refractory (r/r) pediatric B cell acute lymphoblastic leukemia (ALL). The landmark ELIANA pediatric trial studying tisagen
Autor:
Kevin J. Curran, Barbara Spitzer, Jaap Jan Boelens, Scott T. Avecilla, Richard J. O'Reilly, Esperanza B. Papadopoulos, Madhavi Lakkaraja, Susan E. Prockop, Andromachi Scaradavou, Brian C. Shaffer, Sean M. Devlin, Audrey Mauguen, Sergio Giralt, Farid Boulad, Nancy A. Kernan, Gunjan L. Shah, Ichelle van Roessel, Ann A. Jakubowski, Christina Cho, Miguel-Angel Perales, Michael Scordo, Maria Cancio, Andrew L. Kung, Roni Tamari, Josel D. Ruiz
Publikováno v:
Blood. 136:30-31
Background: Rabbit anti-thymocyte globulin (rATG) is used in allogeneic hematopoietic cell transplantation (alloHCT) to prevent graft versus host-disease (GVHD) and graft rejection. In the T-cell replete setting, post-HCT rATG exposure is variable wi
Autor:
Craig S. Sauter, Sergio Giralt, Ahmet Dogan, Renier J. Brentjens, Xiuyan Wang, Kevin J. Curran, Yvette Bernal, Ashvin N. Singh, Craig H. Moskowitz, Jae H. Park, Brigitte Senechal, Malloury Hall, Terence J. Purdon, Victoria Szenes, Michel Sadelain, Ai Ni, Isabelle Riviere, Sarah Yoo, Matthew J. Matasar, Miguel-Angel Perales, Yongzeng Wang
Publikováno v:
Blood
High-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or chemorefractory diffuse large B-cell lymphoma (rel/ref DLBCL). Only 50% of patients are cured with this approach. We investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1b1b7c11bfdf746d55f04610e8be18c
https://europepmc.org/articles/PMC6695562/
https://europepmc.org/articles/PMC6695562/
Autor:
Mary M. Horowitz, Zhen-Huan Hu, Kevin J. Curran, Peiman Hematti, Stephan A. Grupp, Patricia Steinert, Gregory A. Yanik, Joseph Rosenthal, Lan Yi, Michael A. Pulsipher, Amy K. Keating, Raghav Chawla, Eric Bleickardt, Christine Philips, Andrew C. Harris, Yiyun Zhang, Deborah Schiff, Marcelo C. Pasquini, Dana Salzberg, Sarah Nikiforow, Steven P. Margossian
Publikováno v:
Blood. 134:2619-2619
Background Tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy approved for the treatment of patients up to 25 years of age with B-cell ALL that is refractory or in second or later relapse. In the pivotal ELIANA t
Autor:
Ahmet Dogan, Carlos Fernández de Larrea, Oscar B Lahoud, Neha Korde, Kevin J. Curran, Brigitte Senechal, Craig S. Sauter, Nikoletta Lendvai, Pallavi Khattar, Achim A. Jungbluth, Analisa Wills, Mikhail Roshal, Ola Landgren, David J. Chung, Malin Hultcrantz, Maria Lia Palomba, Qi Gao, Claudia Diamonte, Renier J. Brentjens, Michael Scordo, Alexander M. Lesokhin, John Pineda, Sham Mailankody, Terence J. Purdon, Hani Hassoun, Sergio Giralt, Elizabeth Halton, Isabelle Riviere, Gunjan L. Shah, Xiuyan Wang, Jae H. Park, Pavan Anant, Arnab Ghosh, Heather Landau, Eric L. Smith, Mette Staehr, Yvette Bernal
Publikováno v:
Blood. 132:959-959
Introduction: BCMA targeted CAR T cell therapy has shown promising results in patients with relapsed/refractory multiple myeloma (MM). Herein, we report on the safety and efficacy of MCARH171, a second generation, human derived BCMA targeted autologo